Venous thromboembolism (VTE) is a frequent complication of cancer and cancer treatment and is associated with multiple clinical consequences including recurrent venous thromboembolism (VTE), bleeding, and increase in the risk of death. Low molecular weight heparins (LMWH) are often used for long term prophylaxis because of reduced need of coagulation monitoring, few major bleeding episodes and once daily dosing .Low molecular weight heparin have ability to reduce the incidence of VTE and prevent recurrent VT Events in cancer patients. Malignant conditions are frequently associated with a hyper coagulable state, with recurrent thrombosis due to the impact of cancer cells and chemotherapy or radiotherapy on the coagulation cascade. Heparin and, its pharmacokinetically improved versions, low molecular weight heparins are effective in the prevention and treatment of thromboembolic events in cancer patients. This review article explains the role of the thromboprophylaxis in cancer patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.